Copy Link Print Information

Liproxstatin-1

235 Cited Publications
Customer Review

Based on 235 publication(s) in Google Scholar

Liproxstatin-1 is a potent ferroptosis inhibitor and inhibits ferroptotic cell death (IC50=22 nM).

For research use only. We do not sell to patients.

  • Purity: 99.70%
  • CAS No.: 950455-15-9
  • Formula: C19H21ClN4
  • Molecular Weight:340.85
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Liproxstatin-1 Chemical Structure
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Liproxstatin-1 Chemical Structure
    Liproxstatin-1 Chemical Structure
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
  • Experimental Validation Results for Liproxstatin-1
CAS No.: 950455-15-9
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Liproxstatin-1

More
Customer Validation & Images
Flow CytometryIn Vivo ImagingRT-PCRWBCell Proliferation/Viability Assay
  • In Vivo Imaging
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • RT-PCR
Keywords
100 mg
Get Quote In-stock
Please select quantity
Price: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Liproxstatin-1 Chemical Structure
    Liproxstatin-1 Chemical Structure
    1/16
  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2025 Feb 3:80:103528. [Abstract]

    Customer Validation
     Tp53-deficient ID8 tumor-bearing mice were administered with Niraparib (50 mg/kg) from day 6, and administered with Lipro-1 (10 mg/kg, intraperitoneally, a single dose) and SSO (sulfosuccinimidyl oleate) (50 mg/kg, intragastrically, a single dose) from day 3. Representative actual or bioluminescent images of mice after a 3-week treatment.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Nov 5:78:103419. [Abstract]

    Customer Validation
     Cell viability of the control NCI–H358, Calu-1, NCI–H23, MIA PaCa-2 and the corresponding resistant cell lines after 24 h of treatment with the indicated compounds. 2 μM liproxstatin-1 (Lip-1), 10 μM sorafenib or 10 μM lapatinib was used to treat NCI–H358, NCI–H23 and MIA PaCa-2 cells, while Calu-1 cells were treated with 2 μM liproxstatin-1 (Lip-1), 3 μM sorafenib or 10 μM lapatinib (n = 3).

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Dec 5:79:103460. [Abstract]

    Customer Validation
     143B and SJSA-1 cells were treated with SFN with or without Lip-1 (1 μM) for 48 h, and cell viability was evaluated.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Theranostics. 2024 Jul 2;14(10):4090-4106. [Abstract]

    Customer Validation
     Liproxstatin 1 (Lip-1) (48 h) largely reverses the cytotoxicity of ferroptosis inducers enhanced by p62 knockdown in Hela cells.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 May 23:73:103207. [Abstract]

    Customer Validation
     Cell survival of 5FU-R cells treated with a gradient concentration of PUFAs and 10 μM ferrostatin-1, or 10 μM liproxstatin-1 for 24 h.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: J Hazard Mater. 2024 Dec 5:480:135952. [Abstract]

    Customer Validation
     Liproxstatin-1 (100 nM; 50 h) alleviates the decrease in O-GlcNAcylation levels and ferroptosis-related proteins in AML12 cells caused by DON (48 h) exposure.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: MedComm. 2024 Apr 4;5(4):e520. [Abstract]

    Customer Validation
     Antiferroptosis treatment repressed the development of AS in vivo. Normal group: normal diet; HFD group: HFD for 3 months; HFD + ferrostatin‐1 group: HFD accompanied by ferrostatin‐1 treatment (1 mg/kg, twice a day, i.p.); HFD + liproxstatin‐1 group: HFD accompanied by liproxstatin‐1 treatment (10 mg/kg, twice a day, i.p.). IHC of 4‐HEN (ferroptosis marker) in aortic sinus.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Jan 17;10(1):34. [Abstract]

    Customer Validation
     After pretreatment with Fer-1 (10 μM), Lip-1 (2 μM), or DFO (10 μM) for 1 hour, the cells were treated with GLU or NMDA (1 mM) for 24 hours, and then flow cytometry was performed.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Dec;10(36):e2303812. [Abstract]

    Customer Validation
     Cell viability of HEC-1A cells transfected with sh‐PRMT3 and treated with erastin in the absence or presence of liproxstatin‐1 (400 nM), ZVAD‐FMK (10 µM), 3‐methyladenine (1 mM) or necrosulfonamide (10 µM) for 48 h.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Biomaterials. 2024 Jan:304:122430. [Abstract]

    Customer Validation
     Liproxstatin-1 (1 μM). The concentration-dependent cytotoxicity of LysoCOS7, LysoRaw and LysoNeu in the presence of various inhibitors.

  • 1/16

    Liproxstatin-1 purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2019 Nov 5;519(2):240-245. [Abstract]

    Customer Validation
     The ROS and inflammatory cytokines levels increase in acute RILI. The serum levels of inflammatory cytokines increase in RILI. Elisa was used to measure the levels of inflammatory cytokines (TNF-a, IL-6, IL-10 and TGF-b1) at day 15, day 30 and day 60.

  • Liproxstatin-1